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Summary 
Visceral leishmaniasis (VL) causes significant mortality and morbidity in many parts of the world. 
There is an urgent need for the development of new, effective treatments for this disease. We 
describe the development of a novel anti-leishmanial drug-like chemical series based on a 
pyrazolopyrimidine scaffold. The leading compound from this series (5, DDD853651/ 
GSK3186899) is efficacious in a mouse model of visceral leishmaniasis and has suitable 
physicochemical, pharmacokinetic and toxicological properties for further development and has 
been declared a preclinical candidate. Detailed mode of action studies indicate that compounds 
from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus 
defining a novel, druggable, target for visceral leishmaniasis. 
 
Introduction:  
Leishmania parasites cause a wide spectrum of human infections ranging from the life-threatening 
visceral disease to disfiguring mucosal and cutaneous forms. Leishmania spp. are obligate 
intracellular parasites of the vertebrate reticuloendothelial system, where they multiply as 
amastigotes within macrophage phagolysosomes; transmission is by blood-sucking sandflies, in 
which they proliferate as extracellular promastigotes. 
Visceral leishmaniasis (VL), resulting from infection with Leishmania donovani and L. 
infantum, causes more than 30,000 deaths annually, of which ~60% occur in India, Bangladesh 
and Nepal1. In 95% of cases, death can be prevented by timely and appropriate drug therapy2. 
However, current treatment options are far from ideal with outcomes dependent upon a number of 
factors including geographical location, the immune status and other co-morbidities of the patient, 
and the disease classification. None of the current front-line treatments for VL, Ambisome, 
miltefosine, paromomycin and antimonials, are ideal for use in resource poor settings, due to issues 
 3 
such as teratogenicity, cost, resistance and / or clinical relapse, prolonged treatment regimens and 
parenteral administration3-5. Thus, there is an urgent need for new treatment options for VL, 
particularly oral drugs. Unfortunately, there are currently no new therapeutics in clinical 
development and few in preclinical development. Drug discovery efforts have been hampered by 
a paucity of well-validated molecular drug targets in Leishmania, while whole cell (phenotypic) 
screening programs have been hindered by extremely low hit rates 6. Here, we report the discovery 
of an exciting new anti-leishmanial compound with a novel mechanism of action. 
 
Discovery  
Recently, we reported the identification of a diaminothiazole series from a compound screen 
against Trypanosoma brucei GSK3 kinase (TbGSK3)7. During compound optimization it became 
clear that the anti-trypanosomal activity of the series was driven, at least in part, by off-target 
activity. The diaminothiazoles were active against T. brucei bloodstream trypanosomes in viability 
assays, but were essentially inactive against L. donovani axenic amastigotes. Modification of the 
core structure, whilst retaining hydrogen bond donor and acceptor functionalities, gave a bicyclic 
compound series (Fig. 1), one of which (compound 2), showed very weak activity against L. 
donovani axenic amastigotes, but was inactive against the pharmacologically relevant intra-
macrophage amastigotes. However this scaffold was amenable to optimization. Appending a 
sulfonamide to the cyclohexyl ring resulted in compound 3 which was active against L. donovani 
amastigotes in both the axenic and intra-macrophage assays8 and selectively active against L. 
donovani compared to the THP-1 mammalian host cells used in the assay. Modification of the 
substituent on the pyrazole ring resulted in compound 4 which demonstrated >70% parasite 
reduction in a mouse model of VL when dosed orally. 
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Subsequent optimization of the series led to the discovery of the key compound DDD853651 
/ GSK3186899 (compound 5)9, which is our preclinical compound. Compound 5 was active 
against L. donovani in an intra-macrophage assay8 with an EC50 of 1.4 µM (95% CI 1.2-1.5 µM, 
n=12) and good selectivity against mammalian THP-1 cells (EC50 >50 µM). The compound was 
also active and cytocidal in our cidal axenic amastigote study (EC50 0.1 µM (95% CI 0.06-0.17 
µM, n=4)10. At a concentration of 0.2 µM, compound 5 was cytocidal at 96 h; increasing the 
concentration to 1.8 µM reduced this to 48 h (Extended Data Fig. S1). Screening compound 5 
against a panel of Leishmania clinical isolates demonstrated a less than 10-fold variation in 
potency across different strains. The compound was also more active in a panel of leishmanial 
strains using human peripheral mononuclear cells as host cells (Extended Data Table 1). 
Good solubility in relevant physiological media proved key for development of this series; 
compound solubility in Fasted State Simulated Intestinal Fluid (FaSSIF solubility) was used to 
drive the optimization (Extended Data Table 2). Compound 5 was stable in microsomes and 
hepatocytes, predictive of good metabolic stability (Extended Data Table 3). The compound was 
orally bioavailable and showed a linearity of pharmacokinetics from 10 to 300 mg/kg in rats 
(Extended Data Table 4). In a mouse model of VL infection the compound demonstrated 
comparable activity to the front-line anti-leishmanial drug miltefosine, reducing parasite levels by 
99% when dosed orally twice a day for 10 days at 25 mg/kg (Extended Data Table 5). 
The non-clinical safety data for compound 5 suggests a suitable therapeutic window for 
progression into regulatory preclinical studies. In vitro assays demonstrated that this compound 
did not significantly inhibit cytochrome P450 enzymes, which can lead to problematic drug-drug 
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interactions that are particularly relevant due to the frequency of VL/HIV co-infections1. As the 
series was developed from a known protein kinase scaffold11,12, Cellzome’s kinobeadTM 
technology was used to determine if compound 5 potentially inhibits human protein kinases13. 
These experiments indicated that compound 5 interacted with four human kinases, MAPK11, 
NLK, MAPK14 and CDK7, at concentrations within multiples of the predicted clinical dose 
(Table S1). However, the extent of inhibition of these human kinases is not sufficient to preclude 
clinical development of the molecule and no significant inhibition of other human kinases was 
detected in the KinobeadsTM assays. Preclinical assessment of cardiovascular effects and 
genotoxicity did not reveal any issues that would prevent further development. Additionally, there 
were no significant adverse effects in a rat 7-day repeat dose oral toxicity study with respect to 
clinical chemistry and histopathology. Both the in vivo efficacy and safety profile of compound 5 
support progression to definitive safety studies. 
 
Mode of Action Studies 
Elucidating the mode of action of novel chemical series can greatly benefit drug discovery 
campaigns14. Since there is no blueprint to establish the mode of action of bioactive small 
molecules15,16, several complementary methodologies were employed using representative 
pyrazolopyrimidine analogues from the drug discovery program as chemical tools (Fig. 2a). These 
compounds showed very good activity correlation between the intra-macrophage, axenic 
amastigote and promastigote assays, which gave us confidence to use the extracellular parasite 
forms for mode of action studies where it was not possible to use the intracellular forms (Table 
S2). 
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As a first step towards identifying the target(s) of the leishmanocidal pyrazolopyrimidine 
series, a derivative was prepared with a polyethyleneglycol (PEG) linker (9; Fig. 2b) and 
covalently attached to magnetic beads to allow for chemical proteomics. Two methods were used. 
Firstly, the beads were used to pull down proteins from SILAC (Stable Isotope Labelling by Amino 
Acids in Cell Culture) labelled L. donovani promastigote lysates17 in the presence (“light-labelled 
lysate”) or absence (“heavy-labelled lysate”) of 10 µM compound 10, a structurally related, 
bioactive derivative of compound 9 (Fig. 2)18. After combining the bead eluates and performing 
proteomic analyses, proteins that bound specifically to the pyrazolopyrimidine pharmacophore 
could be distinguished from proteins that bound non-specifically to the beads by virtue of high 
heavy : light tryptic peptide isotope ratios. These experiments identified CRK12, CRK6, CYC9, 
CRK3, MAPK9, CYC6 and STE11 as specific binders to the compound 9-derivatised beads (Log2 
heavy : light ratio >2.8; 7-fold enrichment) (Fig. S5; Table S3). In a second experiment, pull down 
experiments were conducted with beads derivatized with 9, 11 or 12, followed by competition 
studies with 7, 6 and 6, respectively. Adherent proteins were washed off the beads, digested with 
trypsin and labelled with isobaric tandem mass tags. Comparison of the labelled peptides derived 
from experiments with and without competition by liquid chromatography/ mass spectrometry 
identified proteins likely to specifically bind to the immobilized ligands. Potential candidates 
identified included: CRK3, CRK6, CRK12 CYC3, CYC6, CYC9, MAPK9, MAPK5 and several 
hypothetical proteins (Fig. S6; Table S4). Although such binding could be direct or indirect as part 
of a protein complex, these results are consistent with previous studies which report that the 
pyrazolopyrimidine core binds to protein kinases11,19-21. One of these binding kinases MAPK9 was 
not considered further as it is not expressed in the disease-relevant Leishmania amastigotes life-
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cycle stage22. We also investigated immobilizing the compound at an alternate position on the 
scaffold and this gave a similar profile (Fig. S6), further validating the approach. 
The presence of three cyclin related kinases (CRK3, 6 and 12) and three cyclins (CYC3, 6 
and 9) in the initial target list led us to analyze the effects of four pyrazolopyrimidines (6, 7, 8 and 
5) on cell-cycle progression in L. donovani. Treatment resulted in an accumulation of cells in G1 
and in G2/M and a decrease in the proportion of cells in S phase (see Fig 3a for data for 5), 
suggesting blocks in the cell-cycle at G1/S and G2/M. These results are consistent with a mode of 
action via CRK and/or CYC components. 
Resistance was generated in L. donovani promastigotes in vitro against compounds 4 and 7, 
with individual clones showing > 500-fold and 9- to 17-fold resistance, respectively (Extended 
Data Table 6). Resistance to both compounds was found to be stable over 50 days in culture in the 
absence of drug pressure and, significantly, all clones showed cross-resistance to 4 and 7, and 20– 
and 50-fold cross-resistance to 5. These data suggest our pyrazolopyrimidines share common 
mechanisms of resistance and therefore modes of action. Importantly, intracellular amastigotes, 
derived from the resistant promastigotes, were 8.5-fold and 5-fold resistant to 7 and 5, respectively, 
compared to wild-type parasites (Extended Data Table S7). These data strongly suggest that the 
mechanism of action of these compounds is the same in promastigote and intracellular amastigote 
stages of the parasite.  
To gain further insight into the mechanism of action and potential target(s) of this 
pyrazolopyrimidine series, we undertook a whole genome sequencing approach. Three clones 
independently selected for resistance to compound 4 and three clones independently selected for 
resistance to compound 7 were used to identify new mutations relative to parental, passaged-
control clones (Table S5). A range of mutations were found across the genome (Table S5), 
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including a long region with loss of heterozygosity on chromosome 9. In total, 75 sites were 
identified genome-wide that each had single base substitutions resulting in a non-synonymous 
change in at least one clone (Table S6). The majority (65) of non-synonymous substitutions 
consisted of derived clones losing a parental allele but amplifying the remaining allele. In five of 
the six resistant clones a new heterozygous substitution was selected in a single gene of unknown 
function (LdBPK_251630) but most strikingly, in all 6 drug-resistant clones, a single homozygous 
non-synonymous substitution was found in CRK12 (LdBPK_090270), a gene within the long loss-
of-heterozygosity region. This mutation changes Gly572 to Asp and falls within the region 
predicted to encode the catalytic domain of L. donovani CRK12. This suggests that CRK12 is the 
target of the pyrazolopyrimdines. Extensive variations in chromosomal copy numbers are common 
in Leishmania23,24, and extra copies of chromosome 9, which contains the CRK12 gene, were found 
in four out of six drug-resistant clones (Table S7). Additionally, three of these four clones had 
extra copies of chromosome 32, which contains the gene for CYC9. Previous studies in T. brucei 
have established that the partner cyclin of CRK12 is CYC925. Taken together, these data suggest 
that CYC9 may be the cognate cyclin partner for L. donovani CRK12. Further CYC9 was 
identified alongside CRK12 in almost all chemical proteomics studies (vide infra). 
 
Target validation 
To dissect the role of CRK12 and CYC9 in the mechanism of action and resistance of 
pyrazolopyrimidines a series of protein overexpression studies were undertaken in L. donovani 
promastigotes. In all cases, overexpression of putative targets was confirmed by elevated levels of 
transcripts in our transgenic cell lines relative to WT, as determined by qRT-PCR (Table S8).  
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Counter-intuitively, overexpression of wild-type CRK12 (CRK12WT) rendered the 
parasites ~3-fold more sensitive to 7. The overexpression of CYC9 alone had no effect on 
compound resistance, but co-overexpression of CYC9 and CRK12WT rendered the transgenic 
parasites ~3-fold resistant to compounds 5 and 7 (Fig. 3c). Next, we looked at the mutated (Gly572 
to Asp) version of CRK12 (CRK12MUT) identified in all 6 of our drug-resistant clones. As 
expected, overexpression of CRK12MUT rendered the parasites ~3.4-fold resistant to 7 (Fig. 3b and 
Table S8) and to the pre-clinical lead compound 5, while being equally sensitive to the unrelated 
nitroimidazole drug fexinidazole sulfone (Table S4). Co-overexpression of CRK12MUT and CYC9 
rendered the parasites ~6-fold resistant to compound 5 and ~8-fold resistant to compound 7. This 
shift in sensitivity is considerably greater than the 3.4-fold resistance observed with parasites 
overexpressing CRK12MUT alone (Fig. 3b). 
Initially, CRK3 and CRK6 were identified as credible targets based upon our collective 
proteomics datasets, as well as their established roles in kinetoplastid cell cycle regulation26,27. 
However, whole genome sequencing, qPCR (Fig. S8) and Southern blot (Fig. S7) analysis of 
resistant clones confirmed that mutations within, or amplification of, the CRK3 and CRK6 genes 
were not responsible for resistance to pyrazolopyrimidines. Direct modulation of CRK3 and CRK6 
levels within L. donovani promastigotes, by generating overexpressing and single gene knockout 
parasites, did not alter drug sensitivity (Table S8).  Overexpression of CRK3 and CRK6 in 
combination with their cognate cyclin partners CYC6 and CYC3 was not possible since co-
overexpression proved toxic. Collectively, these data suggest that the primary mechanism of action 
of this compound series is unlikely to be via CRK3 or CRK6 inhibition.  
Commonly, overexpression of a compound’s molecular target is accompanied by an 
increase in drug resistance. With this in mind, our collective data strongly suggest that the principal 
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target of our pyrazolopyrimidine series is the CYC9-activated form of CRK12, such that 
overexpression of CRK12 and CYC9 together provides resistance. This hypothesis is also 
consistent with the amplification of both CRK12 and CYC9 genes in resistant parasites; as well as 
the identification of both proteins in our SILAC and kinobeadTM proteomic datasets. That 
overexpression of CYC9 alone has no effect suggests that CYC9 is, to some extent, in excess over 
CRK12 and thus overexpression of CRK12MUT can provide (~3-fold) resistance that is increased 
when additional CYC9 is co-expressed (~8-fold). The “hyper-sensitivity” of parasites 
overexpressing CRK12WT alone to these compounds remains perplexing. One potential 
explanation is that CRK12WT bound to a pyrazolopyrimidine in the absence of a CYC9 subunit is 
particularly toxic to the parasite. Alternatively, elevated levels of CRK12 may well sequester other 
cyclins thereby preventing their essential interactions with other CRKs. Further studies will be 
required to test these hypotheses.  
Given that the compounds from this chemical series were found to interact with protein 
kinases, in particular CRK12, we used Cellzome’s KinobeadTM technology13,28,29 with L. donovani 
axenic amastigote extracts to identify pyrazolopyrimidine-binders in the Leishmania kinome. 
These experiments were performed in the presence or absence of an excess of the soluble parent 
compound 7. All proteins captured by the beads were quantified by TMT tagging of tryptic 
peptides followed by LC-MS/MS analysis30. CRK12, MPK9, CRK6 and CYC3 were identified, 
consistent with the other experiments above. A dose response experiment was performed in which 
7 was added over a range of concentrations in order to establish a competition-binding curve and 
determine a half-maximal inhibition (IC50) value (Fig. 4b). The IC50 values obtained in these 
experiments represent a measure of target affinity, but are also affected by the affinity of the target 
for the bead-immobilized ligands. The latter effect can be deduced by determining the depletion 
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of the target proteins by the beads, such that apparent dissociation constants (Kdapp) can be 
determined which are largely independent from the bead ligand30. The apparent dissociation 
constants (Kdapp) were determined to be 1.4 nM for CRK12, 45 nM for MAPK9, 58 nM for CYC3 
and 97 nM for CRK6. These values are determined in physiological conditions and provides 
further compelling evidence that the principal target of this compound series is CRK12. Further 
pull-downs with a resin-bound pyrazolopyrimidine analogue (11) were conducted in parallel with 
the KinobeadTM experiments and returned broadly similar results (Fig 4 c, d) 
 
Modelling 
A homology model was built for L. donovani CRK12 using the structure of human cyclin 
dependent kinase 9 (CDK9, PDB code:4BCF) as a template. (Interestingly 5 showed an IC50 > 20 
µM against CDK9 in the KinobeadsÔ assay.) A combination of docking studies, molecular 
dynamics simulation and free energy calculations indicated the most likely binding mode is that 
shown in Figure 5 (see supporting information for discussion). With very few exceptions, the 
binding modes of protein kinase inhibitors are highly conserved across kinase family members; 
searching the protein database revealed a related 5-amino pyrazolopyrimidine, which bound to 
ALK in a very similar fashion (PDB code 4Z55, ligand 4LO). In our proposed binding mode, the 
bicyclic scaffold interacts with the hinge residues establishing two hydrogen bond between the sp2 
pyrimidine nitrogen in position 6 and the backbone NH of Ala564 and between the pyrazole NH 
in position 1 and the backbone carbonyl oxygen of Ala562 (Fig. 5b). A third hydrogen bond is also 
established between the amino NH in position 5 and the backbone carbonyl oxygen of Ala564. 
The substituent in position 3 of the pyrazole ring is directed towards the ATP back pocket 
interfacing with the gatekeeper residue Phe561. This binding mode is consistent with the PEG-
linked analogues 10 and 11 retaining activity, with the PEG linkers being attached to water-
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accessible parts of the core. The Gly572Asp mutation causing resistance to the pyrazolopyrimidine 
series is located at the end of the hinge region nine residues from the gatekeeper (Phe563). In the 
Gly572Asp mutant, the negatively charge side chain of the aspartic acid is positioned in close 
contact to the two sp2 oxygen atoms of the sulphonamide moiety leading to an unfavorable 
electrostatic interaction.  
 
Discussion 
Our studies indicate that the principal mechanism of action of our pyrazolopyrimidine compounds 
is through inhibition of CRK12, defining CRK12 as one of very few chemically-validated drug 
targets in Leishmania. Further, our data indicate that CYC9 is the definitive partner cyclin for 
CRK12. The physiological function(s) of CRK12/CYC9 have yet to be determined and the 
availability of our inhibitory pyrazolopyrimidines should assist in probing this aspect of parasite 
biology. 
It is clear from our collective chemical proteomics studies that the pyrazolopyrimidines also 
interact with other Leishmania protein kinases, in particular CRK6 and CRK3, albeit with 
significantly lower affinities than for CRK12. While CRK12 is undoubtedly the principal target of 
this compound series, we cannot rule out the possibility that underlying this mechanism of action 
is an element of polypharmacology. Indeed, inhibition of secondary kinase targets may be 
responsible for some of the phenotypic effects we observe in drug-treated parasites, such as cell 
cycle arrest. 
In summary, we have identified a drug-like, anti-leishmanial compound series with clinical 
level efficacy in a VL mouse model of infection, which acts by an entirely novel mechanism of 
action (principally inhibition of CRK12). The compound DDD853651 / GSK3186899 (compound 
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5) is being advanced towards human clinical trials and is currently undergoing preclinical 
development.  
 
End notes 
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methodology and ethical statements. 
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Figure 1: The evolution of the pyrazolopyrimidine series to give the development compound 5. 
The potencies against axenic amastigotes, intramacrophage amastigotes and against THP-1 cells 
are shown8; data from ≥ 3 independent replicates for cidal axenic and intramacrophage assays. 
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Figure 2 a) Additional compounds from the pyrazolopyrimidine series used for mode of action 
studies. b) Linker-containing pyrazolopyrimidine analogues prepared for mode of action studies. 
Activities in the cidal axenic10 and intramacrophage assays8 are shown (data from ≥ 3 
independent replicates). 
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Figure 3: (a) Cell cycle analysis following treatment with compounds for 8 h.  Untreated cells at 0 h (black) and at 8 h (grey). Cells 
treated with 5x EC50 value of compound 5 for 8 h (white). Differences in the percentage of drug-treated cells in the G1, S and G2 phases 
of the cell cycle were confirmed as statistically significant by using an unpaired Student t test (**, P = 0.01; ***, P = 0.001). (b) Effects 
of CRK12MUT and CYC9 overexpression on the potency of compound 7. Susceptibility to compound 7 is decreased in CRK12MUT-
overexpressing promastigotes (EC50 value of 1.99 ± 0.002 nM, open circles) compared to WT cells (EC50 value of 0.59 ± 0.001 nM open 
squares) and further decreased in CRK12MUT/CYC9 co-overexpressing promastigotes (EC50 value of 4.6 ± 0.05 nM, closed circles). (c) 
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promastigotes overexpressing CRK12WT and CYC9 (EC50 value of 1.43 ± 0.01 nM, closed circles) compared to WT cells (EC50 value 
of 0.5 ± 0.004 nM, open circles). All data are the mean ± SD of triplicate cultures from at least a single experiment.
  
 
 
 
Figure 4. Identification of cyclin dependent related kinases as targets of the 
pyrazolopyrimidine series using a chemoproteomic approach. a) Relative amounts of protein 
captured on KinobeadsÔ in the presence of 10 µM compound 7 compared to vehicle, compared 
in 2 experiments. A log2 scale is used. b) Dose response curves of binding of CRK12, MPK9, 
CYC3 and CRK6 to KinobeadsÔ in the presence of varying concentrations of compound 7.  c) 
Relative amounts of protein captured on 11 in the presence of 10 µM compound 7 compared to 
vehicle, compared in 2 experiments. A log2 scale is used. d) Dose response curves of binding of 
CYC9, CRK12, MPK9, CYC3 and CRK6 to 11-derivatised beads in the presence of varying 
concentrations of 7.  
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Figure 5. Docking poses for a) 4 and b) 5. Dotted purple lines represent H-bonds. The mutated 
residue in position Gate-Keeper + 9 is indicated in purple in the ribbon diagram. 
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Extended Data Figure 1: Rate-of-kill of L. donovani axenic amastigotes by compound 5. Chart 
shows relative luminescence units (RLU) versus time from axenic amastigote rate-of-kill 
experiment with compound 5 (n = 3, error bars = standard deviation). Concentrations are as follows 
(µM): 50, open circles; 16.7, closed circles; 5.6, open squares; 1.85, closed squares; 0.62, open 
triangles; 0.21, closed triangles; 0.069, open inverted triangles; 0.023, closed inverted triangles, 
0.0076, open diamond and 0.0025, closed diamond. 
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Extended Data Table 1. Activity of compound 5 and miltefosine against a panel of 
Leishmania clinical isolates (intra macrophage assay using human peripheral blood 
mononuclear cells) 
 
Strain 
Country 
of origin 
Year 
Compound 5 
EC50 (µM) 
Miltefosine 
EC50 (µM) 
L. donovani LV9 Ethiopia 1967 0.06 0.40 
L. donovani SUKA 001 Sudan 2010 0.10 1.0 
L. donovani BHU1 * India 2002 0.10 0.50 
L. donovani DD8 India 1980 0.13 0.50 
L. infantum ITMAP263 Morocco 1967 0.13, 0.50 0.79 
* Antimony-resistant reference strain 
 
Strains were tested on a single (DD8, SUKA001, BHU1) or two (LV9, ITMAP263) test occasions; 
for ITMAP263 the respective EC50 values are shown. 
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Extended Data Table 2. Solubility of compound 5 in simulated physiological media (4h at 
37°C). 
   
Media Final pH Solubility 
[mg/mL] 
SGF pH1.6 SGF (1.5) 1.12 
Fasted SIF pH6.5 FaSSIF (6.5) 0.017 
Fed SIF pH6.5 FeSSIF (6.5) 0.025 
SGF, Simulated Gastric Fluid; SIF, Simulated Intestinal Fluid. Data for polyform 1. 
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Extended Data Table 3. In vitro metabolic stability data for compound 5. 
 
Species Concentration 
(µM) 
Microsomes Cli 
(mL/min/g tissue) 
Hepatocytes Cli 
(mL/min/g tissue) 
Mouse 0.5 0.52 0.84 
Rat 0.5 <0.5 0.77 
Dog 0.5 <0.4 0.31 
Human 0.5 0.71 0.5 
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Extended Data Table 4. DMPK data for compound 5 
 
 
 Mouse 
(male, CD1) 
Rat 
(male, SD) 
Intravenous 1 mg/kg 1 mg/kg 
Cl (ml/min/kg) 169 ± 50 14 ± 9 
Vdss (L/kg) 4.0 ± 0.5 0.4 ± 0.2 
T1/2 (h) 0.3 ± 0.04 0.4 ± 0.1 
AUC(0-inf) (ng.h/mL) 104 ± 26 1514 ± 782 
Oral 10 mg/kg 10 mg/kg 
Cmax (ng/ml) 561 ± 148 1043 ± 261 
Tmax (h) 2 2 
T1/2 (h) 1.2 ± 0.4 2.5 ± 0.6 
AUC(0-inf) (ng.h/mL) 1463 ± 362 6475 ± 2494 
F% based on AUC(0-inf)  >100 46 ±18 
Oral 100 mg/kg 100 mg/kg 
Cmax (ng/ml) 8813 ± 1966 8470 ± 3750 
Tmax (h) 3 7.3 
T1/2 (h) 2.6 ± 0.8 2.1 ± 0.1 
AUC(0-inf) (ng.h/mL) 39433 ± 23830 61202 ± 23591 
F% based on AUC(0-inf)  >100 40 ± 15 
Oral 300 mg/kg 300 mg/kg 
Cmax (ng/ml) 11393 ± 4212 14833 ± 2676 
Tmax (h) 5 7.3 
T1/2 (h) 2.5 ± 0.6 2.8 ± 0.6 
AUC(0-inf) (ng.h/mL) 66150 ± 636 136333 ± 24846 
F% based on AUC(0-inf)  >100 51 ± 22 
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Extended Data Table 5: Efficacy data for compound 5 
 
Dose 
(mg/kg) Frequency 
Duration 
(days) 
 
Reduction in 
parasite load 
(%) 
50 bid 5 96 
25 bid 10 99 
10 bid 10 49 
3 bid 10 4 
50 uid 5 50 
25 uid 10 89 
50 uid 10 95 
 
The ED50, ED90 and ED99 values for compound 5 following 10 day treatment orally b.i.d. are 10.1 
mg/kg, 17.4 mg/kg and 31.5 mg/kg, respectively. The reported ED90 for miltefosine in a mouse 
model is 27 mg/kg u.i.d. 31,326 
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Extended Data Table 6. Sensitivity of WT and drug-resistant promastigotes to compounds 
within the series. Resistance was generated against compounds 4 and 7.  
 
 
 
 
  
Cell line 
  
4 7 5 
pEC50 (SD) Fold pEC50 (SD) Fold pEC50 (SD) Fold 
Wild type 
(Start clone) 
7 (0.1) 1 8.2 (0.4) 1 7.1 (0.3) 1 
Wild type 
(Age-matched) 
7.1 (0.2) 1 8.2 (0.1) 1 7.3 (0.2) 1 
4-resistant clone 1 < 4.3 >500 7.2 (0.1) 11 5.8 (0.4) 20 
4-resistant clone 2 < 4.3 >500 7.3 (0.1) 7 5.7 (0.2) 24 
4-resistant clone 3 < 4.3 >500 7 (0.2) 17 5.4 (0.1) 48 
7-resistant clone 1 < 4.3 >500 7.1 (0.2) 11 5.5 (0.2) 41 
7-resistant clone 2 < 4.3 >500 7.1 (0.2) 14 5.5 (0.1) 35 
7-resistant clone 3 < 4.3 >500 7.3 (0.1) 9 5.7 (0.1) 22 
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Extended Data Table 7: Sensitivity of WT and compound 7-resistant intracellular 
amastigotes (INMAC) to the compound series. 
 
 
Compound  Cell line pXC50 Host cell pXC50 
Fold 
difference  
7 WT 7.5 <5.3 - 
7 7 RES clone 1 6.6 <5.3 8.5 
5 WT 5.9 <4.3 - 
5 7 RES clone 1 5.2 <4.3 5.0 
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